Licenciatura em Química (Sede)
URI permanente desta comunidadehttps://arandu.ufrpe.br/handle/123456789/26
Siglas das Coleções:
APP - Artigo Publicado em Periódico
TAE - Trabalho Apresentado em Evento
TCC - Trabalho de Conclusão de Curso
Navegar
Item Reposicionamento de fármacos como estratégia no tratamento da COVID-19: uma ênfase em antivirais análogos de nucleosídeos/nucleotídeos(2021-12-16) Silva, Cecilãne Regina Dioclecia da; Oliveira, Ronaldo Nascimento de; http://lattes.cnpq.br/9071551767043294; http://lattes.cnpq.br/1016957179784096In December 2019, a new strain of coronavirus was identified. The SARS-CoV-2 virus is the cause of severe acute respiratory syndrome, being popularly known as COVID-19. COVID-19 has spread throughout the world, being declared a pandemic on March 11, 2020, by the World Health Organization. This disease has already decimated about 5.22 million of the world's population. As it is a new virus, there is still no effective treatment. A generally faster strategy is the repositioning of drugs that have already been approved by competent agencies to treat other diseases, which may, after clinical studies, be indicated to treat the symptoms caused by SARS-CoV-2. The drugs used in these treatments, depending on the stage of the disease, whether effective or not to some degree, were galidesivir, remdesivir, favipiravir, sofosbuvir, tenofovir and ribavirin. It can highlight remdesivir, favipiravir and galidesivir because of their promising tests. This review focused on the last five drugs mentioned, which are nucle-oside/nucleotide analogues. A literature review was carried out with data collection on repo-sitioned drugs according to their effectiveness in the treatment of coronavirus. Thus, we pre-sent an overview of the existing drugs that are being or have been used to reduce the effects of COVID-19. With a view to developing a new specific drug to treat the disease caused by the SARS-CoV-2 virus.Item Síntese de 1H-1,2,3-triazol glicopiranosídeos análogos de nucleosídeos com potencial atividade antiviral(2021-12-09) Silva, Carla Jasmine Oliveira e; Oliveira, Ronaldo Nascimento de; http://lattes.cnpq.br/9071551767043294; http://lattes.cnpq.br/6278050350925332In this work, new nucleoside analogues containing the heterocyclics 1,2,3-triazol and pyrimidine conjugated with glycopyranosides were synthesized. Initially, the construction of our first synthetic block was carried out: the [beta]-azido-glycosides 3a-c, from three subsequent steps. The acetylation reaction of the carbohydrates D-(+)-Glucose, D-(+)-Galactose and L-(+)-Arabinose provided the O-acetyl-glycosides 1a-c, which were used in the next step with a solution 33 % HBr/AcOH to obtain [alfa]-bromo-glycosides 2a-c. Finally, we continued with the azidation reaction that formed the [beta]-azido-glycosides with moderate yields of 49% (3a) and 55% (3b) after crystallization in dichloromethane/ethanol (1:1); and 55% (3b) and 45% (3c) after purification by column chromatography (hexane/ethyl acetate, 8:2). The second synthetic block was prepared from the reaction of the nucleotidic bases, uracil and fluorouracil, with the propargyl bromide which provided the N1-,N3-bis-alkylated pyrimidine bases 4a-b with yields of 88% and 96%. Thus, the triazole nuclei were obtained through the copper-catalyzed 1,3-dipolar cycloaddition reaction between [beta]-azido-glycosides 3a-c and N1-,N3-bis-alkylated pyrimidine bases 4a-c. The disubstituted 1,2,3-triazole derivatives 5a-i were synthesized in excellent yields between 82-99%, and with the reaction time reduced to 1 hour compared to the literature, using 20 mol% of Cu(I) and 20 mol% Et3N.